about
Steam sterilisation of vesicular phospholipid gels.Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes.Liposome size analysis by dynamic/static light scattering upon size exclusion-/field flow-fractionation.Altered activity and physicochemical properties of short cationic antimicrobial peptides by incorporation of arginine analogues.Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay.Asymmetrical flow field-flow fractionation with on-line detection for drug transfer studies: a feasibility study.Filter-extruded liposomes revisited: a study into size distributions and morphologies in relation to lipid-composition and process parameters.Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Field-Flow Fractionation/Multiangle Laser Light Scattering.The Effects of Temperature and Growth Phase on the Lipidomes of Sulfolobus islandicus and Sulfolobus tokodaiiIn vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives.Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis.Oral bioavailability enhancement through supersaturation: an update and meta-analysis.Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride.Archaeal lipids in oral delivery of therapeutic peptides.Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies.Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity.Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.Physicochemical properties of lipid nanoparticles: effect of lipid and surfactant composition.Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro.Erosion and controlled release properties of semisolid vesicular phospholipid dispersions.Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes.The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility.Physicochemical characterization of liposomes after ultrasound exposure - mechanisms of drug release.Ultrasound-mediated destabilization and drug release from liposomes comprising dioleoylphosphatidylethanolamine.5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties.Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics.In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation.Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery.Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.Vesicular phospholipid gels.Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: development and in vitro evaluation.Liposome fractionation and size analysis by asymmetrical flow field-flow fractionation/multi-angle light scattering: influence of ionic strength and osmotic pressure of the carrier liquid.Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface.Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions.Effect of hydroxypropyl-beta-cyclodextrin-complexation and pH on solubility of camptothecin.Camptothecin-catalyzed phospholipid hydrolysis in liposomes.
P50
Q30663287-C3A2C766-CCB1-4A2C-9EE3-D138C72AD8B6Q33243310-676D0D37-54B5-4C99-95BB-60698F57079FQ33260716-0E1DF93F-BA3A-4820-904C-98381890931DQ33426045-4E3F364C-54DD-474E-9F4E-1450F95E6029Q34057786-C8F54A0F-3BE2-4C6F-9647-7D5243E36BF0Q35092346-CD986EB7-07F3-4AC7-B8B4-FCF92893B41CQ35590884-1F24B298-53BC-40DE-88E0-E8FC2C9875ACQ35996590-8EF74177-3BCB-497E-BCB2-B66B9D571311Q36138760-98B4FA66-365D-440F-9BF3-F5D2B0B01575Q37969483-B84E0128-4D00-4AC6-9EBB-3BB96FBE361FQ38098816-9F2122D8-FB38-4FDF-A6D3-31CA93432023Q38571316-DDA8AE39-032E-4C2C-A275-5068798214FAQ38917369-7A02C821-52F3-4C91-8A2E-DB13AC5AFA38Q38997239-09D40410-C6B0-48C6-B51B-79846AFFF490Q39096991-5116AC23-32D4-415C-ABA6-EA4F03CAA850Q39263714-028EE885-DF46-4948-AC56-844E8594D67AQ39447406-DC8D5BFC-96C9-4896-8A59-63006486C036Q39508657-EC73C4B2-137F-41ED-87A8-D2743CF8546BQ39664447-6C252CD6-8E00-4189-8BDC-FD0EE46E3BA2Q39795941-6D4C4C1A-E01F-4099-82FB-35AB4E8BFE6BQ40478902-1F9A547E-60F4-4D85-B594-F19E8E7C618AQ40837679-D1CADAA5-1922-4781-9A32-8B8EF8FB2954Q40915619-A8F8D9ED-01D7-41AE-BB15-6E69962D6771Q41335984-4983205E-4668-4952-B3BA-470765087B49Q41611364-48375228-B517-4741-88C4-B66B6766CB46Q41616537-975E6CB5-2C98-42D5-A397-980CE007917FQ41629363-A4609FF7-AB99-4CDC-9434-C7CF5C9E52D4Q41630854-D6FA7AB1-2240-49C1-A019-71B8C03FC483Q42840452-AA5D4EEF-437F-4387-ACA1-06812A343743Q43071626-338E74A2-CFD3-4F3B-9F6B-ED7A29928BF1Q43077642-195529F7-8E20-4EA9-BD6F-FDE72600DF89Q43155644-EC8040F8-3CEC-428E-B511-5E57047F705BQ43194944-436E16B4-B99D-4980-9D34-AD5DDBFBD748Q43238617-FDE63782-F31C-4F33-B70D-E4B0CF5D0CBAQ43245558-B1461558-8002-4BA5-9F3F-35C2F5BB3776Q43971548-1542D40C-48B9-4732-8BF4-8BD1C0B63965Q44752312-405873E3-9046-410F-B35E-8E717658920BQ44798428-810FF86C-EE1E-4612-951B-FC2EEFE12BBDQ45083165-B0465DFE-E948-42D3-8944-962A74FD22B4Q45192824-E0F9A600-0ED8-4F92-AC0A-FBAFCC34E1C4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Martin Brandl
@ast
Martin Brandl
@en
Martin Brandl
@es
Martin Brandl
@sl
type
label
Martin Brandl
@ast
Martin Brandl
@en
Martin Brandl
@es
Martin Brandl
@sl
prefLabel
Martin Brandl
@ast
Martin Brandl
@en
Martin Brandl
@es
Martin Brandl
@sl
P106
P1153
7005162776
P21
P31
P496
0000-0003-3561-5016